BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
It took nearly 50 years to work out the identity of a caribou-like fossil first discovered by construction workers.
Language model delivers predictions that rival years of lab work.